drugset / Trial / NCT03357133

Tirofiban for Patients Treated With Alteplase

NCT03357133

Phase 2/3 Terminated 30 enrolled Capital Medical University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

After intravenous thrombolysis, the overall recanalization rate is 46%, and recclusion after initial recanalization occurs in 14-34%. In the MR TEA, the investigators compared the effects of administration of tirofiban in acute ischemic stroke patients treated with intravenous alteplase thrombolysis with alteplase alone.

Timeline

Start
2017-12-16
Primary completion
2020-06-01
Completion
2020-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Tirofiban Other / unclassified
Comparator Alteplase Protein / enzyme biologic Intravenous

Indications